Trial Profile

A Phase III Clinical Study of BAY1817080 for Refractory Chronic Cough

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 14 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eliapixant (Primary)
Indications Cough
Focus Registrational; Therapeutic Use
Sponsors Bayer

Most Recent Events

04 Feb 2022 According to a Bayer media release, company announced the discontinuation of Phase II development candidate eliapixantthat was being evaluated for potential indications in endometriosis, refractory chronic cough, overactive bladder and diabetic neuropathic pain. Following a review of available data, Bayer concluded that the overall benefit no longer outweighs the risk in these indications.
04 Feb 2022 Status changed from planning to withdrawn prior to enrolment, according to a Bayer media release.
05 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com